Skip to main content

Advertisement

SpringerLink
Log in

Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics

  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Studies conducted at the US National Cancer Institute (NCI) and in our laboratory show that databases including the drug sensitivities of panels of many human cancer cell lines provide valuable information on the molecular pharmacology of anticancer drugs. We established a panel of 39 cell lines of various human cancers and developed a database of their chemosensitivities. Drugs were profiled in terms of their "fingerprints", patterns of differential activity against the cell lines. There was a significant correlation between a drug's fingerprint and its mode of action, as observed in the NCI panel of 60 cell lines. Therefore our cell-line panel is a powerful tool to predict the modes of action of new compounds. We have been using this system for drug discovery, coupled with various target-based drug screenings. We used the system to identify a novel DNA minor-groove binder, MS-247, which has inhibitory activity against topoisomerases I and II, and potent in vivo antitumor activity against various human cancer xenografts. We also discovered a potent novel telomerase inhibitor, FJ5002, by mining our database with the COMPARE algorithm, followed by experimental validation. We investigated the gene expression profiles of the cell lines by using DNA microarrays to find profiles determining cellular chemosensitivity and new targets for anticancer drugs. Our integrated database, including the chemosensitivities and gene expression profiles of the cell-line panel, could provide a basis for drug discovery and personalized therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

References

  1. Boyd MR (1989) Status of the National Cancer Institute preclinical antitumor drug discovery screen: implications for selection of new agents for clinical trial. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology update, vol 3. Lippincott Williams & Wilkins, Philadelphia, p 1

  2. Dan S, Yamori T (2001) Repression of cyclin B1 expression after treatment with adriamycin, but not cisplatin in human lung cancer A549 cells. Biochem Biophys Res Commun 280:861

    Article  CAS  PubMed  Google Scholar 

  3. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T (2002) An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. Cancer Res 62:1139

    CAS  PubMed  Google Scholar 

  4. Di Francesco AM, Ruggiero A, Riccardi R (2002) Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 59:1914

    PubMed  Google Scholar 

  5. Hashimoto S, Xu Y, Masuda Y, Aiuchi T, Nakajo S, Uehara Y, Shibuya M, Yamori T, Nakaya K (2002) β-Hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn J Cancer Res 93:944

    CAS  PubMed  Google Scholar 

  6. Hosokawa N, Iinuma H, Takeuchi T, Sato S, Yamori T, Tsuchiya KS, Hori M (2000) Anticancer and some biological activities of thiazinotrienomycin B. J Antibiot (Tokyo) 53:306

    Google Scholar 

  7. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrichi M, Campbell H, Mayo J, Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757

    CAS  PubMed  Google Scholar 

  8. Naasani I, Seimiya H, Yamori T, Tsuruo T (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59:4004

    CAS  PubMed  Google Scholar 

  9. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088

    Article  CAS  PubMed  Google Scholar 

  10. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Van de Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO (2000) Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24:227

    Article  CAS  PubMed  Google Scholar 

  11. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, Pommier Y, Botstein D, Brown PO, Weinstein JN (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24:236

    Google Scholar 

  12. Shawver LK, Slamon D, Ullrich A (2002) Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1:117

    Article  CAS  PubMed  Google Scholar 

  13. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, Monks AP, Scudiero DA, Sausville EA, Zaharevitz DW, Bunow B, Viswanadhan VN, Johnson GS, Wittes RE, Paull KD (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275:343

    CAS  PubMed  Google Scholar 

  14. Yamori T, Sato S, Chikazawa H, Kadota T (1997) Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn J Cancer Res 88:1205

    CAS  PubMed  Google Scholar 

  15. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T (1999) Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. Cancer Res 59:4042

    CAS  PubMed  Google Scholar 

  16. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN (2002) Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 62:1688

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

I would like to thank Dr. Robert Shoemaker of the Developmental Therapeutics Program, NCI, for his generous help in starting the human cancer cell-line panel system in Japan. I appreciate the collaboration of the members of Screening Committee of New Anticancer Agents supported by grant-in-aid for scientific research on priority areas from the Ministry of Education, Culture, Sports, Science and Technology, Japan. I also thank Ms. Kanami Yamazaki for her assistance in operating the human cancer cell-line system.

Author information

Authors and Affiliations

  1. Division of Molecular Pharmacology, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-ku, 170-8455, Tokyo, Japan

    Takao Yamori

Authors
  1. Takao Yamori
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takao Yamori.

Additional information

This work was presented at the 18th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, "New Strategies for Novel Anticancer Drug Development", 8–9 November 2002, Nagoya, Japan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamori, T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. Cancer Chemother Pharmacol 52 (Suppl 1), 74–79 (2003). https://doi.org/10.1007/s00280-003-0649-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0649-1

Keywords

Search

Navigation